A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)
Document Type
Conference Proceeding
Publication Date
10-20-2023
Publication Title
Annals of Oncology
Abstract
ESMO Congress 2023, October 20 - 24, 2023, Madrid, Spain
First Page
S1204
Last Page
S1205
Volume
34
Issue
Supplement 2
Recommended Citation
Pachynski, Russell Kent; Chatta, Gurkamal S.; Jain, Rohit K.; Moon, Helen H.; Sweis, Randy F.; Delacroix, Scott; Fang, T.; Fling, Steven P.; Lacroix, Andreanne; Kaiser, Judith; Sharon, Elad; and Yu, Evan Y., "A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)" (2023). School of Medicine Faculty Publications. 2384.
https://digitalscholar.lsuhsc.edu/som_facpubs/2384
10.1016/j.annonc.2023.09.1016
Comments
Abstract #2367P